Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition

Br J Haematol. 2018 Jun;181(6):837-840. doi: 10.1111/bjh.14705. Epub 2017 Apr 25.

Authors

Ida Hude^{1

2}, Stephanie Sasse¹, Paul J Bröckelmann¹, Bastian von Tresckow¹, Jesko Momotow¹, Andreas Engert¹, Sven Borchmann¹

Affiliations

¹ German Hodgkin Study Group (GHSG), Department I of Internal Medicine, University Hospital Cologne, Cologne, Germany.
² Department of Internal Medicine, Division of Haematology, University Hospital Centre Zagreb, Zagreb, Croatia.

PMID: 28439879
DOI: 10.1111/bjh.14705

No abstract available

Keywords: Hodgkin lymphoma; biomarkers; eosinophils; immune checkpoint inhibition; immunotherapy.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Autografts
Disease-Free Survival
Eosinophils
Female
Hematopoietic Stem Cell Transplantation*
Hodgkin Disease* / blood
Hodgkin Disease* / mortality
Hodgkin Disease* / therapy
Humans
Leukocyte Count
Male
Middle Aged
Nivolumab / administration & dosage*
Predictive Value of Tests
Programmed Cell Death 1 Receptor / antagonists & inhibitors*
Retrospective Studies
Survival Rate

Substances

PDCD1 protein, human
Programmed Cell Death 1 Receptor
Nivolumab

Associated data

ClinicalTrials.gov/NCT02181738